Sheba Medical Center
Acute lymphoblastic leukemia treatment cost in Israel typically involves a comprehensive diagnosis of leukemia ranging from $3,200 to $5,500. Primary treatments like bone marrow transplantation run from $144,000 to $225,600, while an allogenic bone marrow transplantation from an unrelated donor costs $135,000 to $211,500. Total expenses depend on the clinical stage and protocol complexity, offering 30-80% savings compared to the US. Leading care is concentrated in Tel Aviv, Jerusalem, and Haifa.
Typical Acute Lymphoblastic Leukemia Treatment Costs in Israel
Bookimed Expert Insight: Pediatric patients achieve superior outcomes at specialized centers like Schneider Children's Medical Center. For complex adult cases, Sourasky Medical Center offers a 90% oncology success rate with JCI-accredited standards. Patients requiring advanced cellular therapies should consider Hadassah Medical Center. There, Professor Polina Stepensky has performed over 3,500 bone marrow transplants, specializing in rare blood cancers and innovative gene therapies.
| Israel | Turkey | Austria | |
| Chemotherapy for breast cancer | from $22,500 | from $1,200 | from $15,000 |
| Bone marrow transplantation | from $144,000 | from $36,000 | from $140,000 |
| Autologous bone marrow transplantation | from $58,000 | from $31,500 | from $50,000 |
| Allogenic bone marrow transplantation from an unrelated donor | from $135,000 | from $80,000 | from $180,000 |
| Allogenic bone marrow transplantation from a related donor | from $142,000 | from $65,000 | from $150,000 |
Dr. Ram Ron works within one of Israel's leading and largest public teaching hospitals, the Sourasky Medical Center (Ichilov), known for its high-level patient care and medical innovation.
Dr. Ron Ram has performed several hundred stem cell transplants, a key procedure for acute lymphoblastic leukemia, as a board-certified hematologist-oncologist.
Dr. Ronit El Hasid has performed over 300 bone marrow and umbilical blood transplantations for children at Dana Dwek Children’s Hospital.
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.